Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 5, 2012, Pages 910-911

  Beheshti, Mohsen ^a   Langsteger, Werner ^a  

^a St Vincent's Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE;

BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LETTER; PROSTATE CANCER;

BONE AND BONES; BONE NEOPLASMS; CHOLINE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84862513331     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2046-z     Document Type: Letter

References (9)

1. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [(11)C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26. doi:10.1007/s00259-011-1920-z.
2. Beheshti M, Vali R,Waldenberger P, Fitz F, Nader M, LoidlW, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008;35:1766-74.
3. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-4.
4. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39:396-407. doi:10.1053/j.semnuclmed.2009.05.003.
5. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42.
6. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009;11:446-54.
7. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-8.
8. Beheshti M, Vali R, Nader M, Poecher S, Stoiber F, Fitz F, et al. Potential value of F-18 fluor choline PET-CT in detection of bone metastases in patients with prostate cancer. J Nucl Med 2007;48 (Suppl 2):193P.
9. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36:73-92.